Hospital General Universitario Gregorio Marañón

About: Hospital General Universitario Gregorio Marañón is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Transplantation. The organization has 11975 authors who have published 12386 publications receiving 244847 citations.

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates

Abstract: The in vitro activity of the oxazolidinone linezolid was compared with the activities of vancomycin and teicoplanin against 450 Gram-positive clinical isolates, including a variety of multiply resistant strains. Linezolid inhibited all microorganisms tested at < or = 4 mg/L, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci and viridans streptococci, and erythromycin-resistant beta-haemolytic streptococci. The MIC(90) of linezolid for all isolates was 2 mg/L.

Arthritis in patients with chronic hepatitis C virus infection.

Abstract: Objective To describe the clinical picture of arthritis in patients with chronic infection by hepatitis C virus (HCV) Methods Two patient populations were studied Patients with arthritis and evidence of serum elevation of alanine aminotransferase (ALT) at the consultation were checked for HCV infection A second group of 303 consecutive patients with rheumatoid arthritis (RA) were also checked for the presence of HCV antibodies All patients attended the outpatient rheumatology unit of a tertiary care teaching hospital Chronic HCV infection was determined by the presence of viral RNA in serum A group of 315 first-time blood donors served as controls Results Twenty-eight patients with arthritis and chronic HCV infection were identified Seven fulfilled criteria for RA, psoriatic arthritis was found in one patient, systemic lupus erythematosus in one, gout in 2, chondrocalcinosis in 2, osteoarthritis in 7, and tenosynovitis in one In 7 patients with a clinical picture of intermittent arthritis, a definitive diagnosis could not be made In these patients, mixed cryoglobulinemia was present in 6/7 (86%), whereas mixed cryoglobulinemia was found in 6/21 (28%) of the other patients Among patients with RA, 23 (76%) had HCV antibodies, and active infection by HCV was found in 7 (23%) patients The prevalence of HCV antibodies in a blood donor population was 095%, significantly different (p Conclusion There is not a single clinical picture of arthritis in patients with chronic HCV infection There is a well defined picture of arthritis associated with the presence of mixed cryoglobulinemia that consists of an intermittent, mono or oligoarticular, nondestructive arthritis affecting large and medium size joints Although a high prevalence of HCV antibodies is suspected in patients with RA, its occurrence may be coincidental and its interpretation is difficult to determine from the data in this study

Predictores de mortalidad hospitalaria y a medio plazo tras el reemplazo valvular aórtico transcatéter: datos del registro nacional TAVI 2010-2011

Abstract: Resumen Introduccion y objetivos El tratamiento de la estenosis aortica grave sintomatica se ha revolucionado con la tecnica de reemplazo valvular aortico transcateter. El objeto del presente estudio es presentar la evolucion y los predictores de mortalidad de los pacientes incluidos entre 2010 y 2011 en el Registro Nacional de Reemplazo Valvular Aortico Transcateter. Metodos Se han recogido 131 variables previas al procedimiento; 31 perioperatorias y 76 de seguimiento clinico. Se ha analizado el exito inmediato del implante, la variable combinada de seguridad a los 30 dias y la mortalidad por cualquier causa a 30 dias y al seguimiento maximo (media, 244 dias). Resultados Desde enero de 2010 hasta diciembre de 2011, se ha incluido a 1.416 pacientes: 806 valvulas Edwards y 610 CoreValve. El exito del implante y la mortalidad hospitalaria fueron del 94 y el 9% respectivamente, sin diferencias entre valvulas y accesos. La variable combinada de seguridad a 30 dias y la mortalidad al seguimiento maximo fueron del 14 y el 16% del total respectivamente, tambien similares entre grupos de valvulas y accesos. La presencia de comorbilidades (insuficiencia renal, enfermedad vascular periferica, fraccion de eyeccion y fibrilacion auricular), la necesidad de conversion a cirugia y la insuficiencia aortica al menos moderada tras el implante se identificaron como predictores independientes de mortalidad a medio plazo. Conclusiones La seleccion del paciente teniendo en cuenta su comorbilidad y la optimizacion del resultado para minimizar el grado de insuficiencia aortica residual pueden mejorar el pronostico de estos pacientes.